Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
4.070
-0.080 (-1.93%)
Dec 3, 2024, 12:59 PM EST - Market open
Perspective Therapeutics Employees
As of December 31, 2023, Perspective Therapeutics had 119 total employees, including 116 full-time and 3 part-time employees. The number of employees increased by 53 or 80.30% compared to the previous year.
Employees
119
Change
53
Growth
80.30%
Revenue / Employee
$13,084
Profits / Employee
-$536,008
Market Cap
276.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
uniQure | 480 |
Lexicon Pharmaceuticals | 285 |
Vanda Pharmaceuticals | 203 |
Nyxoah | 147 |
Aclaris Therapeutics | 91 |
Atai Life Sciences | 83 |
aTyr Pharma | 59 |
Rezolute | 51 |
CATX News
- 6 days ago - Perspective Therapeutics to Participate in Upcoming Investor Conferences in December - GlobeNewsWire
- 12 days ago - Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium - GlobeNewsWire
- 17 days ago - Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 - GlobeNewsWire
- 20 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine - GlobeNewsWire
- 6 weeks ago - Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey - GlobeNewsWire
- 7 weeks ago - Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report - Benzinga